Low Dose Clonazepam for Autism - SFARI Webinar with William Catterall






Click this link  http://sfari.org/sfari-community/community-blog/webinar-series/2015/webinar-william-catterall-examines-anxiety-drugs-for-autism/


This post will be mainly of interest to the small number of people using low-dose clonazepam for autism and those considering doing so.

This therapy modifies the excitatory/inhibitory (im)balance between the GABA and Glutamate neurotransmitters.  The big advantage is that it should be very safe, is extremely inexpensive and, unlike Bumetanide, does not cause diuresis.   The disadvantage is that the effective dose is only in a narrow window, and you have to find it by trial and error.


Does it work?

It certainly does work in some children with autism.

It also appears to have an additional effect over Bumetanide alone, at least my son.

Questions remain:

·        Does it work with everyone who responds to bumetanide?
·        Does it only work in people with a Nav1.1 dysfunction?
·        Will bumetanide work in everyone who responds to Clonazepam?


One of my earlier, detailed, posts on this subject is this one:-

Channelopathies in Autism - Treating Nav1.1 with Clonazepam


Just google “clonazepam epiphany” or use the site index, for the other posts.


Professor Catterall

I have already covered the science behind low-dose Clonazepam and Professor Catterall’s trials in two mouse models.  It is quite a complex subject and in the end most people just want to know does it work in humans with autism or not.

Catterall’s research was funded by the Simons Foundation, so no surprise really that he made a Webinar for SFARI.  It covers the ground of those two papers and indicates the next steps for his research.

It is a bit lighter going than his papers, but it is a full hour of science.

Catterall plans to trial it in humans with autism, starting with those known to have sodium channel dysfunction. So he is following the same pattern he used with his mice.

The first mouse model he used was Dravet syndrome, a rare condition leading to epilepsy and autism which is caused by a sodium ion channel (Nav1.1) dysfunction.  The second experiment used a standard mouse model of autism called the BTBR mouse model, so no connection with sodium channels.

My question to Catterall was whether this therapy would only work in people with a Nav1.1 dysfunction.  He did respond via the comments on the post, but did not really answer the question.  The fact that he plans to trial his idea on humans with autism with a known sodium ion channel dysfunction, does suggest something at least.

I think that since the actual mechanism of the drug is on a sub-unit of the GABAA receptor, sodium channels may actually be more of a coincidence, meaning that while autism Nav1.1 dysfunction may indeed indicate this therapy, it may be applicable in other autism where GABA is dysfunctional.


Bumetanide Use

The downside of bumetanide use to correct the E/I imbalance often found in autism is the diuresis and excessive loss of potassium in about 20% of people.

If you revisit the original paper suggesting an  E/I imbalance might be fundamental to many kinds of autism, you will see that this E/I imbalance is not just an ongoing issue, it is potentially an avoidable cause of disruption at key points in the brain’s development prior to maturation. In simpler terms, an E/I imbalance during development may cause the physical brain abnormalities often observed in autism.

That would suggest you should try and reverse E/I imbalance as soon as possible, well before maturation of the brain. 

One day an analog of bumetanide may be developed, that avoids the diuresis;  it is already being discussed.


Bumetanide (or low dose Clonazepam) use, even before autism has become established ?


In something like 30% of cases of classic autism there is macrocephaly (a big head), which even shows up on ultrasound scans of the pregnant mother.  A big head does not necessarily mean autism, but specific types of autism are clearly associated with big heads.

There are many other well known risk factors, like siblings with autism, siblings with other disabilities, older parents, family history (schizophrenia, bipolar, auto-immune conditions, COPD, Nobel Laureates, math prodigies) etc.

Since we also know that an indicator of this kind of E/I imbalance is that benzodiazepine drugs can show paradoxical effects (they work in reverse), it should be possible to make some kind of predictive diagnostic test.


So it would not be rocket science to identify many babies at elevated risk of autism and then treatment could be started very early and well before brain maturation.

This is rather like the Japanese researchers in the previous post suggesting that sulforaphane consumption in childhood might prevent susceptible people developing schizophrenia in adulthood.








Comments

Post a Comment

Popular posts from this blog

mTOR – Indirect inhibition, the Holy Grail for Life Extension and Perhaps Some Autism

Image
  Not cheap at about $1,000 for just 140mg Life extension may come as a surprise, but it is interesting because it is well studied and, in mice at least, easy to measure.  Most research into mTOR relates to cancer, but this is a very complex condition. With various feedback loops it means that sometimes the actual effect is the opposite of what was predicted.  For example, a substance that can help prevent cancer can actually become harmful later and promote its growth. Direct inhibition of mTOR with Everolimus and similar drugs (variants/analogs of Rapamycin , all called Rapalogs) has not been as successful as hoped in cancer research.  Trials of direct inhibition of mTOR will shortly start in one rare single gene type of autism ( TSC ).  The drugs are so expensive that many providers do not want to pay for them. As you will see mTOR is just one process in a cloud of interrelated processes.   Almost everything has a role/effect:- growth factors, cytokines,...
Read more

Zinc, Hedgehog Signaling, Shank2/3, NMDA/AMPA Inactivation and Autism

Image
I am gradually tying up the loose ends in this blog. Today several issues are dealt with that are all connected by zinc. Some are extremely complicated and I will skip over the details. Not that kind of hedgehog 1.      In those rather complicated graphics in the literature that explain signaling pathways, you may have noticed something called hedgehog signaling. This is a basic pathway present in all bilaterians - creatures with a head and tail/feet and a left and right. So flies, yes; but jelly fish, no.   In autism there is excessive hedgehog signaling.   Zinc deficiency is linked to activation of the hedgehog signaling pathway 2.      One of the commonly used models of autism is called Shank3; there is another one called Shank2.   Shank proteins are scaffold proteins that connect neurotransmitter receptors and ion channels to the actin cytoskeleton and G-protein-coupled signaling pathways.   Mutations in these genes are ass...
Read more

Bravo Monty! Academic results in Autism

Image
  Some risks are worth taking, however long the journey Academic results are part of most people’s life, whether you love them or loathe them. Most children diagnosed today with autism will do just fine at school, but this was not always the case.   Those born 20 or 30 years ago and diagnosed in early childhood with autism are usually in a much less fortunate position. Today’s post is about level 3 autism and what the Lancet Commission want to call Profound autism. The new idea is that if by age of 8, a child with autism still has severe intellectual disability or minimal language then he/she can be best described as having Profound Autism. In other literature the term SDA (Strictly Defined Autism) was proposed.   I t means what was called autism back in the 1990s and earlier. You can have severe autism with any level of IQ, which I think many people may not be aware of, or even accept.   Monty and his Academic Results The “bravo” for Monty comes from Dr Ben-A...
Read more